The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
Anti-CD20 monoclonal antibody
Booster immunization
Hematologic diseases
Hypogammaglobulinemia
SARS-CoV-2 vaccine
Journal
Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
03
01
2022
revised:
22
04
2022
accepted:
27
05
2022
pubmed:
7
6
2022
medline:
4
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
The HEMVACO study evaluated the humoral response after mRNA anti-SARS-CoV-2 vaccination in an hematological cohort. HEMVACO was a prospective, multicentric study registered in ClinicalTrials.gov, number NCT04852796. Patients received two or three doses of BNT162b2 vaccine or mRNA-1273 vaccine. The SARS-CoV-2 TrimericS IgG titers were measured 1, 3, 6 and 12 months after the second dose. Only 16 patients (11.6%) were naive of hematological treatment and 77 patients (55.8%) were on active treatment for hemopathy. Among the 138 analyzed patients, positive antibody titer at 1 month was obtained in 68.1% of patients with mean serology at 850±883 BAU/ml. Risk factors for vaccine failure were anti-CD20 therapy (OR=111[14.3-873]; P<0.001), hypogammaglobulinemia under 8g/L (OR=2.49[1.05-5.92]; P=0.032) and lymphopenia under 1.5G/L (OR=2.47[1.18-5.17]; P=0.015). Anti-CD20 therapy induced no anti-SARS-CoV-2 seroconversion (96%). Seventy-eight patients (56.5%) received a third dose and could reach the SARS-CoV-2 TrimericS IgG titer of high-risk patients (P=0.54). The median titer at 379 BAU/ml distinguished two groups of vaccine response (99±121 BAU/ml versus 1,109±678 BAU/ml). Vaccination should be performed before anti-CD20 therapy if the hemopathy treatment can be delayed. Administration of the third vaccine dose was interesting for patients with suboptimal response, defined by a 379 BAU/ml titer in our study.
Identifiants
pubmed: 35667558
pii: S2666-9919(22)00098-7
doi: 10.1016/j.idnow.2022.05.008
pmc: PMC9164434
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
RNA, Messenger
0
Vaccines
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Banques de données
ClinicalTrials.gov
['NCT04852796']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-285Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Références
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Eur J Cancer. 2020 Sep;136:4-6
pubmed: 32619884
Lancet Haematol. 2021 May;8(5):e312-e314
pubmed: 33811822
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
Blood Cells Mol Dis. 2021 Mar;87:102525
pubmed: 33338697
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Oct 21;385(17):1627-1629
pubmed: 34525276
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Blood. 2002 Sep 15;100(6):2257-9
pubmed: 12200395
Clin Infect Dis. 2021 Dec 6;73(11):2000-2008
pubmed: 34134134
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572